Literature DB >> 17085054

Synthesis and antitumor activities of a series of novel quinoxalinhydrazides.

Fedora Grande1, Francesca Aiello, Osvaldo De Grazia, Antonella Brizzi, Antonio Garofalo, Nouri Neamati.   

Abstract

Recently, we discovered a novel class of anticancer compounds with remarkable potency in a panel of cancer cell lines. A prototype compound, SC144, showed significant in vivo efficacy in mice xenograft models of human breast cancer cells. Herein, we report on a new synthetic route to SC144 and the synthesis of several of its analogues in order to understand required features for activity. A one-step coupling of 7-fluoro-4-chloropyrrolo[1,2-a]quinoxaline with pyrazin-2-carbohydrazide improved the yield significantly. Although several of the analogues showed significant activities, modification of the heteroacyl moiety had a dramatic effect on potency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085054     DOI: 10.1016/j.bmc.2006.09.073

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  15 in total

1.  Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.

Authors:  Rajkumar Rajule; Vashti C Bryant; Hernando Lopez; Xu Luo; Amarnath Natarajan
Journal:  Bioorg Med Chem       Date:  2012-02-16       Impact factor: 3.641

2.  2,3-Substituted quinoxalin-6-amine analogs as antiproliferatives: a structure-activity relationship study.

Authors:  Qianyi Chen; Vashti C Bryant; Hernando Lopez; David L Kelly; Xu Luo; Amarnath Natarajan
Journal:  Bioorg Med Chem Lett       Date:  2011-02-17       Impact factor: 2.823

3.  Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.

Authors:  Xiaojuan Wu; Yang Cao; Hui Xiao; Chenglong Li; Jiayuh Lin
Journal:  Mol Cancer Ther       Date:  2016-08-17       Impact factor: 6.261

Review 4.  An Overview of Coumarin as a Versatile and Readily Accessible Scaffold with Broad-Ranging Biological Activities.

Authors:  Francesca Annunziata; Cecilia Pinna; Sabrina Dallavalle; Lucia Tamborini; Andrea Pinto
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

5.  NVX-412, a new oncology drug candidate, induces S-phase arrest and DNA damage in cancer cells in a p53-independent manner.

Authors:  Alexandra Hebar; Barbara C Rütgen; Edgar Selzer
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

6.  N'-[(E)-4-Benz-yloxy-2-hy-droxy-benzyl-idene]-4-nitro-benzohydrazide monohydrate.

Authors:  Bibitha Joseph; M Sithambaresan; M R Prathapachandra Kurup
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-04-18

7.  Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer.

Authors:  S Xu; H Adisetiyo; S Tamura; F Grande; A Garofalo; P Roy-Burman; N Neamati
Journal:  Br J Cancer       Date:  2015-06-23       Impact factor: 7.640

8.  Biological evaluation, docking and molecular dynamic simulation of some novel diaryl urea derivatives bearing quinoxalindione moiety.

Authors:  Sedighe Sadeghian-Rizi; Ghadamali Ali Khodarahmi; Amirhossein Sakhteman; Ali Jahanian-Najafabadi; Mahboubeh Rostami; Mahmoud Mirzaei; Farshid Hassanzadeh
Journal:  Res Pharm Sci       Date:  2017-12

9.  N'-[(E)-4-Benz-yloxy-2-hy-droxy-benzyl-idene]-4-nitro-benzohydrazide di-methyl-formamide monosolvate.

Authors:  Bibitha Joseph; M Sithambaresan; M R Prathapachandra Kurup
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-06-26

10.  Synthesis and characterization of some novel diaryl urea derivatives bearing quinoxalindione moiety.

Authors:  Sedighe Sadeghian-Rizi; Ghadamali Khodarahmi; Amirhossein Sakhteman; Ali Jahanian-Najafabadi; Mahboubeh Rostami; Mahmoud Mirzaei; Farshid Hassanzadeh
Journal:  Res Pharm Sci       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.